Expression of CD133 and ABCB5 is associated with tumor aggressiveness, but evidence in papillary thyroid cancer (PTC) is lacking. We correlated CD133 and ABCB5 expression with pathological characteristics and factors of worse prognosis in PTC. Samples of 119 PTCs and 40 controls (goiters) were distributed in 8 tissue microarray blocks and evaluated with immunohistochemistry using anti-CD133 and anti-ABCB5 antibodies. The expression of each marker alone and combined was analyzed against pathological characteristics and factors of worse prognosis in PTC. Expression of CD133 alone (19 tumors, 16.0%) was more frequent in patients with versus without lymph node metastases (P=0.024). Expression of ABCB5 alone (n=95, 83.3%) was associated with larger tumor size (P=0.045). CD133-ABCB5 coexpression was not associated with pathological characteristics or factors of worse prognosis in PTC.

CD133和ABCB5的表达与肿瘤的侵袭性有关，但缺乏甲状腺乳头状癌（PTC）的证据。我们将CD133和ABCB5表达与PTC的病理特征和预后较差的因素相关联。将119个PTC和40个对照（甲状腺肿）的样本分布在8个组织微阵列模块中，并使用抗CD133和抗ABCB5抗体通过免疫组织化学进行评估。针对PTC的病理特征和预后较差的因素分析了单独和组合使用的每种标志物的表达。与相比，单独的CD133（19个肿瘤，16.0％）的表达更为频繁无淋巴结转移（P = 0.024）。单独表达ABCB5（n = 95，83.3％）与更大的肿瘤大小相关（P = 0.045）。CD133-ABCB5共表达与PTC的病理特征或预后较差的因素无关。